• Skip to main navigation
  • Skip to main content
  • Skip to Footer
  • Ireland
    • Novartis Website Directory
Novartis Logo: a global healthcare company
  • Our Work
    • Therapeutic Areas
    • Clinical Trials
    • Our Process
    • Product Portfolio
  • About Us
    • Who We Are
    • Our Business
    • Corporate Responsibility
    • Contact Us
  • For Patients
    • Commitment to Patients and Caregivers
    • Working with Patient Groups
    • Media Contacts
  • Careers
    • Career Search
    • Working at Novartis Ireland
    • Employee Benefits
    • Awards & Recognition
    • Well-being
Search
My Migraine Voice Report
  • TwitterTweet
  • FacebookShare
  • Share
    • Twitter
    • Facebook
    • LinkedIn
    • Email
    • Whatsapp
  • Jump to Comments
Stories/Education & Awareness

Novartis Ireland launch My Migraine Voice Survey Report in Cork

Jun 17, 2019

This newly published survey on Irish people with frequent and severe migraine reveals the condition is having a significant negative impact on their lives, including damaging their career progression and earnings. Migraine is Ireland’s fifth leading cause of disability, affecting almost one in eight peoplei. While it affects people of all ages and genders it is three times more common in women than men. Despite its high prevalence, migraine remains a misunderstood and under-managed conditionii. This new survey, which focusses on the small section of the population who have at least four migraines per month, was part of a global patient study undertaken by Novartis in partnership with the European Migraine and Health Alliance in 36 countries, to establish how frequent and severe migraine affects daily life. The Irish results were presented by Dr Edward O’Sullivan who runs the Migraine Clinic in Cork University Hospital, other speakers on the day included Deputy Michael McGrath TD, Mr Patrick Little, CEO of the Migraine Association of Ireland, Dr Sean O’Sullivan, Consultant Neurologist Bon Secours Hospital Cork and Louise O’Sullivan who gave her individual perspective on living with migraine.

PDF iconMy Migraine Voice Report.pdf

 

 

Disclaimer: 

i Vos T, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015 The Lancet Volume 388, Issue 10053, 8–14 October 2016, Pages 1545-1602.

ii Migraine generally features a one-sided throbbing headache that is episodic and lasts hour or even days with total freedom between attacks. Classical migraine (migraine with aura) may be signalled by visual disturbances in what is call the “aura” stage. This affects about 20% of migraneurs. Common migraine (or migraine without aura) and classical migraine may be accompanied by vomiting, diarrhoea, confusion and, in rare cases, temporary paralysis and loss of speech. Sensitivity to light, noise and strong smells is also frequently reported.

    • TwitterTweet
    • FacebookShare
    • Share
      • Twitter
      • Facebook
      • LinkedIn
      • Email
      • Whatsapp
    • Jump to Comments
  • Print
  • Save

Novartis Stories

View all

Migraine_Patient_Survey_Image
Education & Awareness

Majority of Migraine Sufferers Report Experiencing More Frequent and Severe Migraines During Pandemic

Image of work space
Education & Awareness

MS Ireland and Novartis launch video series to support the wellbeing of those living with multiple sclerosis (MS) during Covid-19 pandemic

Elderly couple looking at papers
Education & Awareness

‘We’ll See You’ Campaign - Urges Irish Public to Keep Eye Care Appointments and Be Vigilant for Signs of Age-Related Macular Degeneration

You are here

  1. Home ›
  2. Stories ›
  3. Education & Awareness

Novartis Ireland

  • News
  • Careers
  • About Us
  • Contact Us
  • Locations
  • Our Work

Subscribe to Novartis

  • Facebook
  • Twitter
  • YouTube
  • LinkedIn
  • Instagram
  • Email
  • Novartis Site Directory
© 2021 Novartis AG

This site is intended for an audience in Ireland.

  • Terms of Use
  • Privacy Policy
  • Accessibility
  • Cookie Settings